Clinical trial registry record

Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Withdrawn.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 19, 2022.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04919096
Last registry update
April 19, 2022
Status
Withdrawn
Phase
Phase 1
Sponsor
Clover Biopharmaceuticals AUS Pty
Enrollment
0
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
0
Population
ALL · 50 Years
Duration
2022-04-01 to 2023-01-01
Intervention
SCB-420; Aflibercept
Comparator
Aflibercept
Outcomes measured
Incidence of ocular and non-ocular adverse events. — Baseline to Week 12; Change from baseline in Best Corrected Visual Acuity (BCVA) — Baseline to Week 12; Change in central foveal thickness (CFT) — Baseline to Week 12; Percentage Change from baseline in the area of Choroidal neovascularization (CNV) lesions in Neovascular Age-related Ma…; Observe serum concentration of free and total SCB 420 and Eylea — Baseline to Week 8; Observe maximum concentration (Cmax) of free and total SCB 420 and Eylea — Baseline to Week 8; Observe minimum concentration (Cmin) of free and total SCB 420 and Eylea — Baseline to Week 8; Observe Time to Maximum concentration (Tmax) of free and total SCB 420 and Eylea — Baseline to Week 8; Observe Elimination Half Life (T1/2) of free and total SCB 420 and Eylea — Baseline to Week 8; Titer of anti-drug antibodies (ADAs) against SCB-420 and Eylea at predose on Day 1, Week 4, and Week 8 — Baseline to We…; Neutralizing antibodies testing in confirmed ADA positive subjects — Baseline to Week 8
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON